Abstract
A series of new potential anticonvulsants have been synthesized. They are N-methyl benzylamides of N-methyl Asp and N-methyl Glu (R and S), benzylamides of some heterocyclic acids and their Noxides and benzylamides of two heteroalicyclic acids. The obtained compounds were evaluated in the Anticonvulsant Screening Project (ASP) of Antiepileptic Drug Development Program (ADDP) of NIH.
Keywords: anticonvulsants, n-methyle-glu, n-methyl-asp derivatives, heterocyclic acid derivaties
Protein & Peptide Letters
Title: Anticonvulsant Activity Of Benzylamides Of Some Amino Acids And Heterocyclic Acids
Volume: 10 Issue: 5
Author(s): Ryszard Paruszewski, Marzanna Strupinska, Grazyna Rostafinska-Suchar and James P. Stables
Affiliation:
Keywords: anticonvulsants, n-methyle-glu, n-methyl-asp derivatives, heterocyclic acid derivaties
Abstract: A series of new potential anticonvulsants have been synthesized. They are N-methyl benzylamides of N-methyl Asp and N-methyl Glu (R and S), benzylamides of some heterocyclic acids and their Noxides and benzylamides of two heteroalicyclic acids. The obtained compounds were evaluated in the Anticonvulsant Screening Project (ASP) of Antiepileptic Drug Development Program (ADDP) of NIH.
Export Options
About this article
Cite this article as:
Paruszewski Ryszard, Strupinska Marzanna, Rostafinska-Suchar Grazyna and Stables P. James, Anticonvulsant Activity Of Benzylamides Of Some Amino Acids And Heterocyclic Acids, Protein & Peptide Letters 2003; 10 (5) . https://dx.doi.org/10.2174/0929866033478636
DOI https://dx.doi.org/10.2174/0929866033478636 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
CNS & Neurological Disorders - Drug Targets Pharmacotherapy of Borderline Personality Disorder: A Systematic Review
Current Medicinal Chemistry Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Phytochemical Analysis with Antioxidant and Cytotoxicity Studies of the Bioactive Principles from Zanthoxylum capense (Small Knobwood)
Anti-Cancer Agents in Medicinal Chemistry Neurotransmitter Regulation of Adult Neurogenesis: Putative Therapeutic Targets
CNS & Neurological Disorders - Drug Targets GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling
Current Medicinal Chemistry Rational Drug Design and the Discovery of the Δ2-1,2,3-Triazolines, A Unique Class of Anticonvulsant and Antiischemic Agents
Current Medicinal Chemistry The Effect of Protein Restriction in the In Vitro Metabolism of Albendazole in Rats
Drug Metabolism Letters Genetic and Environmental Factors in Complex Neurodevelopmental Disorders
Current Genomics Enzymes as Target Antigens of Liver-Specific Autoimmunity: The Case of Cytochromes P450s
Current Medicinal Chemistry Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews Curcumin, Resveratrol and Cannabidiol as Natural Key Prototypes in Drug Design for Neuroprotective Agents
Current Neuropharmacology Metabolic Basis of Sporadic Alzeimer’s Disease. Role of Hormones Related to Energy Metabolism
Current Pharmaceutical Design Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) Biological Evaluation of Imidazobenzoxazines, Imidazobenzoxazin-5-ones and Imidazobenzoxazin-5-thiones as Sodium Channel Blockers
Letters in Drug Design & Discovery ERRATUM 2
Current Neuropharmacology Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design